NasdaqGS:ADPTLife Sciences
Adaptive Biotechnologies (ADPT) Raised MRD Guidance, Is The Stock Fairly Valued?
Q2 earnings report and raised MRD guidance put Adaptive Biotechnologies in focus
Adaptive Biotechnologies (ADPT) drew fresh investor attention after reporting second quarter 2026 results and updating its full year outlook for the Minimal Residual Disease, or MRD, business.
The company reported quarterly sales of US$71.55 million and a net loss of US$39.79 million. It also raised expected 2026 MRD revenue to a range of US$268 million to US$278 million.
See our latest analysis for Adaptive...